IONS Q4 2021 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$440M+51.6% YoY

Gross Profit

$438M99.5% margin

Operating Income

$221M50.1% margin

Net Income

$225M51.0% margin

EPS (Diluted)

$1.41

QoQ Revenue Growth

+230.6%

Cash Flow

Operating Cash Flow

$204M

Free Cash Flow

$200M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$1.8B

Stockholders' Equity

$772M

Cash & Equivalents

$869M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$440M	$290M	+51.6%
Gross Profit	$438M	$287M	+52.5%
Operating Income	$221M	-$23M	+1073.3%
Net Income	$225M	-$340M	+166.0%

Revenue Segments

Research and Development Revenue Under Collaborative Agreements

$353M63%

Commercial

$87M16%

Spinraza Royalties

$69M12%

TEGSEDI and WAYLIVRA

$40M7%

Licensing and Other Royalties

$10M2%